{"entity":{"id":"pazopanib","kind":"drug","name":"Pazopanib","aka":[],"tldr":"Pazopanib is the only multi-kinase inhibitor approved for soft-tissue sarcoma (excluding fat-derived tumours), used after chemotherapy fails.","summary":"Pazopanib is an ATP-competitive inhibitor of VEGFR1-3, PDGFR alpha and beta, KIT and FGFR that starves tumours of new blood vessels. It is the only multi-kinase inhibitor approved for soft-tissue sarcoma and is used after chemotherapy fails. In PALETTE, patients with non-adipocytic soft-tissue sarcoma after anthracycline had PFS 4.6 versus 1.6 months on placebo (HR 0.31) but no OS benefit, and the FDA approved it in April 2012; liposarcoma was excluded after poor phase 2 results. It was first approved in 2009 for advanced renal cell carcinoma, where newer combinations have largely displaced it. Liver enzyme elevation carries a boxed warning, hypertension affected 41%, fatigue 65%, and pneumothorax in about 3% is a sarcoma-specific concern; Novartis markets it. Pazopanib delays progression in sarcoma without clearly extending life, a trade-off weighed against its side effects.","status":"approved","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Pazopanib","links":[{"label":"FDA label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pazopanib"}],"tags":[],"related":[],"cancers":["sarcoma","rcc","angiosarcoma","alveolar-soft-part-sarcoma"],"sections":[],"technologies":["kinase-inhibitors","antiangiogenic"],"targets":["vegf","kit"],"drugs":[],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07087158"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Votrient","modality":"Small-molecule kinase inhibitor (VEGFR/PDGFR/KIT)","mechanism":"ATP-competitive inhibitor of VEGFR1-3, PDGFRα/β, KIT, FGFR.","approvals":[{"region":"US","year":2009,"indication":"Advanced renal cell carcinoma"},{"region":"US","year":2012,"indication":"Advanced non-adipocytic soft-tissue sarcoma after chemotherapy"}],"mechanismSteps":[],"dosing":{"route":"Oral","schedule":"800 mg once daily on an empty stomach","monitoring":"Liver enzymes (boxed warning), blood pressure, thyroid, QT, pneumothorax in sarcoma"},"toxicity":[{"event":"Hypertension","anyGradePct":41,"grade3PlusPct":7,"note":"PALETTE"},{"event":"Fatigue","anyGradePct":65,"grade3PlusPct":13},{"event":"ALT elevation","grade3PlusPct":8},{"event":"Pneumothorax","anyGradePct":3}],"access":[],"regulatoryEvents":[]},"route":"/drugs/pazopanib/","neighbours":{"cancer":[{"id":"alveolar-soft-part-sarcoma","kind":"cancer","name":"Alveolar soft part sarcoma","route":"/cancers/alveolar-soft-part-sarcoma/"},{"id":"angiosarcoma","kind":"cancer","name":"Angiosarcoma","route":"/cancers/angiosarcoma/"},{"id":"dermatofibrosarcoma-protuberans","kind":"cancer","name":"Dermatofibrosarcoma protuberans","route":"/cancers/dermatofibrosarcoma-protuberans/"},{"id":"desmoplastic-small-round-cell-tumour","kind":"cancer","name":"Desmoplastic small round cell tumour","route":"/cancers/desmoplastic-small-round-cell-tumour/"},{"id":"epithelioid-haemangioendothelioma","kind":"cancer","name":"Epithelioid haemangioendothelioma","route":"/cancers/epithelioid-haemangioendothelioma/"},{"id":"leiomyosarcoma","kind":"cancer","name":"Leiomyosarcoma","route":"/cancers/leiomyosarcoma/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"retroperitoneal-sarcoma","kind":"cancer","name":"Retroperitoneal sarcoma","route":"/cancers/retroperitoneal-sarcoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"extremity-soft-tissue-sarcoma","kind":"cancer","name":"Soft tissue sarcoma of the extremity (localised and advanced)","route":"/cancers/extremity-soft-tissue-sarcoma/"},{"id":"synovial-sarcoma","kind":"cancer","name":"Synovial sarcoma","route":"/cancers/synovial-sarcoma/"},{"id":"undifferentiated-pleomorphic-sarcoma","kind":"cancer","name":"Undifferentiated pleomorphic sarcoma (UPS)","route":"/cancers/undifferentiated-pleomorphic-sarcoma/"},{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/"},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"trial":[{"id":"nct07087158","kind":"trial","name":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","route":"/trials/nct07087158/"},{"id":"aldoxorubicin-phase-3-sts","kind":"trial","name":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma","route":"/trials/aldoxorubicin-phase-3-sts/"},{"id":"nct03260894","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","route":"/trials/nct03260894/"},{"id":"tappas","kind":"trial","name":"TAPPAS","route":"/trials/tappas/"}],"pathway":[{"id":"renal-cell-carcinoma-signalling","kind":"pathway","name":"Renal cell carcinoma (KEGG map)","route":"/pathways/renal-cell-carcinoma-signalling/"},{"id":"angiogenic-switch","kind":"pathway","name":"The angiogenic switch & tumour vessels","route":"/pathways/angiogenic-switch/"}],"drug":[{"id":"carotuximab","kind":"drug","name":"Carotuximab","route":"/drugs/carotuximab/"},{"id":"cediranib","kind":"drug","name":"Cediranib","route":"/drugs/cediranib/"}]}}